Regeneron Pharmaceuticals, Inc.
REGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Regeneron Pharmaceuticals, Inc. focuses on Biotechnology services and products. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. With a market capitalization of $85.22B, it sits in large-cap territory. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
Market Cap
$85.22B
Beta
0.19
P/E (TTM)
20.88
P/E (Fwd)
13.66
EPS (TTM)
$39.65
EPS (Fwd)
$60.61
ROE
14.0%
ROA
6.5%
Cash
$7.99B
Total Debt
$2.71B
Free CF
$3.07B
52W Change
51.0%
Annual Financials
Cash vs Debt
Where REGN stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, REGN finished 10.24% above its 150-day moving average ($720.43) and 9.27% above its 200-day moving average ($726.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is REGN overbought or oversold?
At the August 31, 2026 close, REGN's RSI(14) was 45.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Regeneron Pharmaceuticals, Inc. holds $7.99B in cash against $2.71B in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $3.07B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 14.0%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $12.17B to $14.34B.
With a beta below 0.7, Regeneron Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, REGN has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Regeneron Pharmaceuticals, Inc. and its sector.